Figure 3.

The new proposed model of the risk of progression in the entire series of patients with complete data with (A) and without a bone marrow aspirate (B). Below are depicted the 270 patients with an available bone marrow biopsy, allowing to study the different risks of progression of IgM monoclonal gammopathy of undetermined significance (MGUS) and asymptomatic Waldenström macroglobulinemia (AWM) (C), and the performance of the proposed model based on bone marrow aspirate in patients with bone marrow biopsy (D). PFS, progression‐free survival.